The effects of scopolamine and the nootropic drug phenotropil on rat brain neurotransmitter receptors during testing of the conditioned passive avoidance task
We studied the effects of administration of the new nootropic drug phenotropil (N-carbamoylmethyl-4-phenyl-2-pyrrolidone) at a dose of 100 mg/kg on the quantitative characteristics of dopamine (DA), serotonin (5-HT), glutamate (NMDA), GABA-A (BDZ), and acetylcholine (nACh) receptors in rats using the conditioned passive avoidance task (PAT) under normal conditions and during scopolamine-induced amnesia ex vivo. We found that the cholinolytic drug scopolamine induced a substantial increase in the density (B max) of n-choline receptors in the cortex (by 99% as compared to the control) and NMDA receptors in the hippocampus (by 93%). A single administration of phenotropil (100mg/kg, intraperitoneally) abolished the effect of scopolamine and decreased the number of nACh and NMDA receptors by 46% and 14%, respectively. Phenotropil also abolished the effect of scopolamine on the benzodiazepine receptors and dopamine D1 receptors. Scopolamine decreased the density of D1 receptors by 20% and BDZ receptors by 17%, whereas phenotropil increased the density of receptors by 16% and 25%, respectively. Phenotropil considerably increased the density of dopamine D2 and D3 receptors by 29% and 62%, respectively. Scopolamine also increased the density of D3 receptors by 44% as compared to the control. We did not find any changes in the binding characteristics of 5-HT2 receptors during scopolamine-induced amnesia or during phenotropil treatment. These results demonstrate the role of these receptors in the development of scopolamine-induced amnesia and in neurochemical mechanisms of the anti-amnestic effects of phenotropil.
Keywordsphenotropil nootropic drugs scopolamine PAT dopamine serotonin acetylcholine glutamate benzodiazepines striatum frontral cortex hippocampus
Unable to display preview. Download preview PDF.
- 1.Akhapkina, V.N., Fenotropil. Sb. St., 2007, pp. 6–14.Google Scholar
- 2.Filippova, S.Yu., Aleshina, N.V., and Stepanov, V.P., Fenotropil. Sb. St., 2007, pp. 84–87.Google Scholar
- 3.Kovalev, G.I., Akhapkina, V.I., Abaimov, D.A., and Firstova, Yu.Yu., Atmosfera. Nervnye Bolezni, 2007, no. 4, pp. 22–26.Google Scholar
- 4.Kovalev, G.I. Doctorate (Med.) Dissertation [in Russian], Moscow: NII farmakologii im. V.V. Zakusova, 1993.Google Scholar
- 6.Firstova, Yu.Yu., Cand. Sci. (Biol.) Dissertation [in Russian], Moscow: NII farmakologii im. V.V. Zakusova, 2008.Google Scholar
- 7.Kovalev, G.I. and Prikhozhan, A.V., Farmakologiya nootropov. Eksperimental’noe i klinicheskoe izuchenie. Val’dman A.V., Voronina T.A., Eds., Moscow, 1989, pp. 99–104.Google Scholar
- 8.Kovalev, G., Kudrin, V., Zharikov, S., Pogorelov, V., Bogdanov, M., and Guinetdinov, R., Abstr. of Meeting Dopamine-92, Italy, 1992, p. 29.Google Scholar
- 11.Voronina, T.A. and Ostrovskaya, R.U., in Rukovodstvo po eksperimental’nomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv (Manual on Experimental (Preclinical) Studies of New Pharmacological Compounds), Moscow, 2000, pp. 153–158.Google Scholar
- 13.Alexander, S.P., Mathie, A., and Peters, J.A., Guide to Receptors and Channels. BJP, 2006, vol. 147, no. 3, p. 146.Google Scholar
- 29.Aramakis, V.B. and Metherate, R., J. Neurosci., 1998, vol. 18, pp. 257–263.Google Scholar